Indications

BEEF AND NON-LACTATING DAIRY CATTLE

BRD – AROVYN Injectable Solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis; and for the control of respiratory disease in cattle at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis.
IBK – AROVYN Injectable Solution is indicated for the treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis.
FOOT ROT – AROVYN Injectable Solution is indicated for the treatment of bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii.

SUCKLING CALVES, DAIRY CALVES, AND VEAL CALVES

BRD – AROVYN Injectable Solution is indicated for the treatment of BRD associated with M. haemolytica, P. multocida, H. somni, and M. bovis.

Diseases

CATTLE

• Bovine respiratory disease (BRD)
  • Histophilus somni
  • Mannheimia haemolytica
  • Mycoplasma bovis
  • Pasteurella multocida
• Infectious bovine keratoconjuntivitus (IBK)
  • Moraxella bovis
• Interdigital necrobacillosis (Foot Rot)
  • Fusobacterium necrophorum
  • Porphyromonas levii

Administration

CATTLE: Inject subcutaneously as a single dose in the neck at a dosage of 2.5 mg/kg (1.1 mL/100 lb) body weight (BW).

Do not inject more than 10 mL per injection site.

AROVYN Cattle Dosing Guide

Contraindications

The use of AROVYN Injectable Solution is contraindicated in animals previously found to be hypersensitive to the drug.

Supplied

50 mL vial
100 mL vial
250 mL vial
500 mL vial

Storage

Store below 30°C (86°F), with excursions up to 40°C (104°F). Use this product within 84 days of the first puncture and puncture a maximum of 20 times. If more than 20 punctures are anticipated, the use of automatic injection equipment or a repeater syringe is recommended. When using a draw-off spike or needle with bore diameter larger than 16 gauge, discard any product remaining in the vial immediately after use.

Warnings

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. NOT FOR USE IN CHICKENS OR TURKEYS.

Residue Warnings

CATTLE: Cattle intended for human consumption must not be slaughtered within 18 days from the last treatment. This drug is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.

Precautions

CATTLE: The effects of AROVYN on bovine reproductive performance, pregnancy, and lactation have not been determined. Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

Adverse Reactions

CATTLE: In one BRD field study, two calves treated with tulathromycin injection at 2.5 mg/kg BW exhibited transient hypersalivation. One of these calves also exhibited transient dyspnea, which may have been related to pneumonia.

Important Safety Information

Arovyn: AROVYN has a pre-slaughter withdrawal time of 18 days in cattle. Do not use in female dairy cattle 20 months of age or older. Do not use in animals known to be hypersensitive to the product. See full Prescribing Information.

Banamine TD: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. Milk that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of the last treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in milk and/or calves born to these cows or heifers. Not for use in beef and dairy bulls intended for breeding over 1 year of age, beef calves less than 2 months of age, dairy calves, and veal calves. Do not use within 48 hours of expected parturition. Approved only as a single topical dose in cattle. For complete information on Banamine® Transdermal, see accompanying product package insert.

Nuflor: Do not use in animals that have shown hypersensitivity to florfenicol or animals intended for breeding purposes. Transient inappetence, diarrhea, decreased water consumption, injection site swelling, anaphylaxis and collapse have been associated with the use of florfenicol in cattle. Do not use in calves to be processed for veal or in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. Animals intended for human consumption must not be slaughtered within 28 days of the last intramuscular treatment or 38 days of subcutaneous treatment. A withdrawal period has not been established in pre-ruminating calves. Avoid direct contact with skin, eyes, and clothing. Pregnant women should wear gloves and exercise caution or avoid handling this product. For complete information, see the product package insert.

Resflor Gold: Not for use in humans. Keep out of reach of children. Do not use in animals that have shown hypersensitivity to florfenicol or flunixin. Avoid direct contact with skin, eyes and clothing as product contains materials that can be irritating. Animals intended for human consumption must not be slaughtered within 38 days treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. Not for use in animals intended for breeding purposes. See package insert for complete information.

Zuprevo: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN. Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. The effects of Zuprevo^®18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

DO NOT USE Zuprevo^®18% IN SWINE. Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

Contact

U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573.
For additional information, please see the product label.